Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry

Article Dermatology

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Christopher E. M. Griffiths et al.

Summary: This study evaluated the efficacy of four years of continuous guselkumab treatment for psoriasis. The results showed that high efficacy response rates were maintained throughout the treatment period.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice

A. Ruggiero et al.

Summary: The study indicated that three anti-IL-23 therapies are promising, safe, and effective options for elderly patients with psoriasis, with no significant differences found between them. However, more data is required to confirm these results and understand their role in the management of this patient group. Limitations of the study included small sample size and varied follow-up durations.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Elena del Alcazar et al.

Summary: This study aimed to assess the effectiveness and safety of guselkumab in the treatment of moderate to severe plaque psoriasis in routine clinical practice. The results showed that guselkumab had significant efficacy and good safety profile at 24 weeks.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Article Dermatology

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry

Jessica A. Walsh et al.

Summary: The study described baseline characteristics of patients with plaque psoriasis initiating guselkumab in a real-world setting, indicating important differences in baseline characteristics according to biologic experience among patients with more severe disease initiating guselkumab.

DERMATOLOGY AND THERAPY (2022)

添加到收藏夹

Article Dermatology

Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry

Clinton W. Enos et al.

Summary: The study found that obesity and a history of diabetes reduce the likelihood of patients responding to biologic treatment, especially in achieving certain levels of disease improvement. Obesity is associated with lower response to TNFi and IL-17i biologics, while diabetes is associated with poorer outcomes when using IL-17i therapy, independent of obesity.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Letter Dermatology

Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study

J. F. B. Schwensen et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Article Dermatology

Psoriasis Prevalence and Severity by Expert Elicitation

Kim A. Papp et al.

Summary: This study used expert elicitation to estimate the prevalence and severity distribution of psoriasis in the adult population. The median prevalence of psoriasis was 3.0%, with 50% of patients having mild disease and 78% having mild or moderate disease. The expert elicitation approach can help guide decision-making in dermatology where evidence is lacking.

DERMATOLOGY AND THERAPY (2021)

添加到收藏夹

Article Dermatology

Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

K. Reich et al.

Summary: Guselkumab maintained high levels of clinical response and improvement in patient-reported outcomes through 252 weeks of treatment in patients with moderate-to-severe psoriasis.

BRITISH JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020

A. M. Orbai et al.

Summary: This study compared work absenteeism and short-term disability among adults with psoriasis or psoriatic arthritis (PsA) versus controls in the USA. The results showed that patients with PsA and psoriasis had higher rates of work absenteeism and short-term disability compared to controls, emphasizing the substantial economic burden of psoriatic disease.

CLINICAL RHEUMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: A prospective real-life study on the Chinese population

Jia-Yi Zhuang et al.

Summary: This study confirmed the short-term effectiveness and safety of guselkumab in Chinese population with psoriasis, as well as its regulatory effect on Tregs. Majority of patients achieved PASI 90 and 100 responses at week 16, and dynamic detection showed stable levels of CD4(+)CD25(+)Foxp3(+) Tregs during guselkumab treatment.

DERMATOLOGIC THERAPY (2021)

添加到收藏夹

Article Dermatology

28095 Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment

Andrew Blauvelt et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Psoriasis Prevalence in Adults in the United States

April W. Armstrong et al.

Summary: The prevalence of psoriasis among US adults was 3.0%, with no significant differences in prevalence by gender, race/ethnicity, marital status, education, income, or medical insurance status. The prevalence has remained stable since 2003.

JAMA DERMATOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice

Yi-Teng Hung et al.

Summary: The real-world effectiveness of guselkumab was found to be compromised, with delayed therapeutic response in heavier patients. Factors such as biologic exposure and previous treatments were identified as clinical predictors of reduced response to guselkumab.

THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2021)

添加到收藏夹

Article Dermatology

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

Kristian Reich et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

添加到收藏夹

Letter Dermatology

Guselkumab: Short-term effectiveness and safety in real clinical practice

Lourdes Fernandez-Freire et al.

DERMATOLOGIC THERAPY (2020)

添加到收藏夹

Letter Dermatology

Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study

A. -C. Fougerousse et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Philip J. Mease et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Atul Deodhar et al.

LANCET (2020)

添加到收藏夹

Article Dermatology

Real-life experience of guselkumab in patients with psoriasis

Igor Snast et al.

DERMATOLOGIC THERAPY (2020)

添加到收藏夹

Article Medicine, General & Internal

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

Marco Galluzzo et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Article Dermatology

Long-term Single Center Experience in Treating Plaque Psoriasis With Guselkumab

Khalad Maliyar et al.

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2020)

添加到收藏夹

Letter Dermatology

Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study

F. Benhadou et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

添加到收藏夹

Review Allergy

The influence of body weight of patients with chronic plaque psoriasis on biological treatment response

Anna Kisielnicka et al.

POSTEPY DERMATOLOGII I ALERGOLOGII (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Psoriasis Pathogenesis and Treatment

Adriana Rendon et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Article Dermatology

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Alan Menter et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry

Bruce Strober et al.

BMJ OPEN (2019)

添加到收藏夹

Article Psychiatry

Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study

Jose M. Martinez-Ortega et al.

JOURNAL OF PSYCHOSOMATIC RESEARCH (2019)

添加到收藏夹

Article Medicine, General & Internal

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

Kristian Reich et al.

LANCET (2019)

添加到收藏夹

Article Dermatology

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

April W. Armstrong et al.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)

添加到收藏夹

Article Dermatology

Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry

Bruce Strober et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

添加到收藏夹

Review Medicine, Research & Experimental

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician

Lawrence Blonde et al.

ADVANCES IN THERAPY (2018)

添加到收藏夹

Article Dermatology

Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study

Andac Salman et al.

ANAIS BRASILEIROS DE DERMATOLOGIA (2018)

添加到收藏夹

Article Dermatology

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial

R. G. Langley et al.

BRITISH JOURNAL OF DERMATOLOGY (2018)

添加到收藏夹

Article Dermatology

Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies

A. B. Gottlieb et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)

添加到收藏夹

Article Dermatology

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial

Andrew Blauvelt et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

添加到收藏夹

Article Dermatology

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial

Kristian Reich et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

添加到收藏夹

Article Medicine, Research & Experimental

The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment

Agnieszka Bozek et al.

ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2017)

添加到收藏夹

Article Dermatology

Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA

N. J. Korman et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Psoriasis

Wolf-Henning Boehncke et al.

LANCET (2015)

添加到收藏夹

Review Biochemistry & Molecular Biology

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases

Michele W. L. Teng et al.

NATURE MEDICINE (2015)

添加到收藏夹

Review Dermatology

The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials

Richard G. B. Langley et al.

JOURNAL OF DERMATOLOGICAL TREATMENT (2015)

添加到收藏夹

Article Dermatology

Heterogeneity of Response to Biologic Treatment: Perspective for Psoriasis

Emily Edson-Heredia et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003-2011

April W. Armstrong et al.

PLOS ONE (2012)

添加到收藏夹

Review Dermatology

How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review

Phyllis I. Spuls et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)

添加到收藏夹

Article Dermatology

Association of patient-reported psoriasis severity with income and employment

Elizabeth J. Horn et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)

添加到收藏夹

Article Dermatology

National Psoriasis Foundation clinical consensus on disease severity

David M. Pariser et al.

ARCHIVES OF DERMATOLOGY (2007)

添加到收藏夹

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry

相关参考文献

导出引文

分享论文